NCT00513786View on ClinicalTrials.gov

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 1, 2007

Primary Completion Date

January 3, 2017

Study Completion Date

January 3, 2017

Conditions
Endometrial Cancer
Interventions
DRUG

Carboplatin

AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.

DRUG

Paclitaxel

175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.

DRUG

bevacizumab

15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.

Trial Locations (1)

43210

The Ohio State University-Division of Gyn Oncology, Columbus

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

David O'Malley

OTHER